Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers

Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

(2020) Daisuke Sueta et al.   CURRENT HYPERTENSION REPORTS

Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis

(2019) Jonatan Barrera-Chimal et al.   KIDNEY INTERNATIONAL

Adverse effects of mineralocorticoid receptor antagonist administration

(2019) Manolis S. Kallistratos et al.   CURRENT PHARMACEUTICAL DESIGN

New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure

(2019) Irene Capelli et al.   JOURNAL OF NEPHROLOGY

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria

(2019) Sadayoshi Ito et al.   Clinical Journal of the American Society of Nephrology

Estimated glomerular filtration rate decline and risk of end-stage renal disease in type 2 diabetes

(2018) Megumi Oshima et al.   PLoS One

The effects of AER and eGFR on outcomes of CVD in patients with T2DM in an urban community over 8 years of multifactorial treatment: the Beijing Communities Diabetes Study 18

(2018) Xue-Lian Zhang et al.   Therapeutics and Clinical Risk Management

A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy

(2017) Shigehiro Katayama et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Aldosterone Blockade in CKD: Emphasis on Pharmacology

(2015) Michael H. Schwenk et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

Evidence-based Clinical Practice Guideline for CKD 2013

(2014)   Clinical and Experimental Nephrology

Aldosterone Blockade in Chronic Kidney Disease

(2014) Jamie S. Hirsch et al.   SEMINARS IN NEPHROLOGY

Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes

(2013) Takashi Wada et al.   Clinical and Experimental Nephrology

Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy

(2013) Thomas A. Mavrakanas et al.   European Journal of Internal Medicine

The Impacts of Albuminuria and Low eGFR on the Risk of Cardiovascular Death, All-Cause Mortality, and Renal Events in Diabetic Patients: Meta-Analysis

(2013) Tadashi Toyama et al.   PLoS One

Metabolic syndrome and risk of progression of chronic kidney disease: a single-center cohort study in Japan

(2012) Takako Saito et al.   HEART AND VESSELS

Mineralocorticoid receptor antagonists: their use and differentiation in Japan

(2012) Atsuhisa Sato   HYPERTENSION RESEARCH

Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension

(2012) GianLuca Colussi et al.   JOURNAL OF HYPERTENSION

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism

(2011) Rena J Eudy et al.   Journal of Translational Medicine